A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM
Tekijät: Nordestgaard BG, Langlois MR, Langsted A, Chapman MJ, Aakre KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-Lercher A, Kolovou G, Kamstrup PR, Mora S, Kronenberg F, Remaley AT, Pulkki K, Ros E, Rifai N, Stavljenic-Rukavina A, Stankovic S, Watts GF, Sypniewska G, Laitinen P, Wiklund O, Laitinen P
Julkaisuvuosi: 2020
Journal: Atherosclerosis
Tietokannassa oleva lehden nimi: Atherosclerosis
Lehden akronyymi: Atherosclerosis
Vuosikerta: 294
Aloitussivu: 46
Lopetussivu: 61
Sivujen määrä: 16
ISSN: 0021-9150
eISSN: 1879-1484
DOI: https://doi.org/10.1016/j.atherosclerosis.2019.12.005
Rinnakkaistallenteen osoite: https://rgu-repository.worktribe.com/preview/795755/SOIKKELI-JALONEN%202020%20Instruments.pdf
The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory diagnostics of atherogenic lipoproteins. Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and calculated non-HDL cholesterol (=total - HDL cholesterol) constitute the primary lipid panel for estimating risk of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state. LDL cholesterol is the primary target of lipid-lowering therapies. For on-treatment follow-up, LDL cholesterol shall be measured or calculated by the same method to attenuate errors in treatment decisions due to marked between-method variations. Lipoprotein(a)-cholesterol is part of measured or calculated LDL cholesterol and should be estimated at least once in all patients at risk of ASCVD, especially in those whose LDL cholesterol decline poorly upon statin treatment. Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-HDL cholesterol or apolipoprotein B, especially in patients with mild-to-moderate hypertriglyceridemia (2-10 mmol/L). Non-HDL cholesterol includes the assessment of remnant lipoprotein cholesterol and shall be reported in all standard lipid panels. Additional apolipoprotein B measurement can detect elevated LDL particle numbers often unidentified on the basis of LDL cholesterol alone. Reference intervals of lipids, lipoproteins, and apolipoproteins are reported for European men and women aged 20-100 years. However, laboratories shall flag abnormal lipid values with reference to therapeutic decision thresholds.
